A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors

Jermaine Coward; Hui Gan; James Kuo; Michael Millward; Gary Richardson; Wei Deng; Siddhartha Mitra; Maike Schmidt; Hong Xiang; Lisa Horvath; Amy Prawira

A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors

Jermaine Coward, Hui Gan, James Kuo, Michael Millward, Gary Richardson, Wei Deng, Siddhartha Mitra, Maike Schmidt, Hong Xiang, Lisa Horvath, Amy Prawira

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal for immunotherapy of cancer
Volume	7
Publication status	Published - 6 Nov 2019

Cite this

@article{81bd625c79764a289949b0e8a010c632,

title = "A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors",

author = "Jermaine Coward and Hui Gan and James Kuo and Michael Millward and Gary Richardson and Wei Deng and Siddhartha Mitra and Maike Schmidt and Hong Xiang and Lisa Horvath and Amy Prawira",

year = "2019",

month = nov,

day = "6",

language = "English",

volume = "7",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BMJ Group",

}

TY - JOUR

T1 - A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors

AU - Coward, Jermaine

AU - Gan, Hui

AU - Kuo, James

AU - Millward, Michael

AU - Richardson, Gary

AU - Deng, Wei

AU - Mitra, Siddhartha

AU - Schmidt, Maike

AU - Xiang, Hong

AU - Horvath, Lisa

AU - Prawira, Amy

PY - 2019/11/6

Y1 - 2019/11/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000496473200862&DestLinkType=FullRecord&DestApp=WOS

M3 - Abstract/Meeting Abstract

SN - 2051-1426

VL - 7

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

ER -

A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors

Other files and links

Cite this